The global head of research and development at Atara Biotherapeutics discussed the future of MS research.
"We're beginning to learn more and more about [Epstein-Barr virus]. This idea that a virus can actually activate an autoimmune cascade that can be very detrimental to particular patients is very important and I think we're going to learn more in the coming years. There's even a recent publication that implicates EBV and reactivation in long COVID. This molecular mimicry with a virus like EBV really seems to have the ability to cause havoc with the immune system, and lead to human pathology.”
A recent publication in Science has elucidated the relationship between multiple sclerosis (MS) and Epstein-Barr virus (EBV), with a high prevalence of EBV infections associated with MS.1 Another paper published soon after in Nature proposed a possible mechanism of how EBV could lead to MS.2
Research and therapeutic development in MS may be influenced by the findings, but this isn’t a new avenue of research for Atara Biotherapeutics, whose cell therapy candidate ATA188 targets EBV-infected cells for the potential treatment of MS. ATA188 is currently being evaluated in the phase 2 EMBOLD study (NCT03283826) and has demonstrated positive data in its phase 1 study and open-label extension.3
CGTLive spoke with Jakob Dupont, MD, global head, research and development, Atara, to learn more about future avenues of research in MS as well as pursuing further research on the relationship between EBV and other autoimmune diseases.
Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy
November 24th 2024In observance of Alzheimer Disease Awareness Month, held annually in November, we took a look back at the past year's news and expert insights in cell and gene therapy for Alzheimer disease.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.